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for women with chronic diseases and
multimorbidity: a population-based cohort study
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Abstract
Background: Chronic diseases and multimorbidity are common in western countries and associated with increased
breast cancer mortality. This study aims to investigate non-participation in breast cancer screening among women
with chronic diseases and multimorbidity and the role of time in this association.
Method: This population-based cohort study used regional and national registries. Women who were invited to the
first breast cancer screening round in the Central Denmark Region in 2008–09 were included (n = 149,234). Selected
chronic diseases and multimorbidity were assessed up to 10 years before the screening date. Prevalence ratios (PR)
were used as an association measure.
Results: The results indicated that women with at least one chronic condition were significantly more likely not to
participate in breast cancer screening. In adjusted analysis, a significantly higher likelihood of non-participation was
found for women with cancer (PR = 1.50, 95 % CI: 1.40–1.60), mental illness (PR = 1.51, 95 % CI: 1.42–1.60), chronic
obstructive pulmonary disease (PR = 1.51, 95 % CI: 1.42–1.62), neurological disorders (PR = 1.24, 95 % CI: 1.12–1.37) and
kidney disease (PR = 1.70, 95 % CI 1.49–1.94), whereas women with chronic bowel disease (PR = 0.75, 95 % CI 0.65–0.88)
were more likely to participate than women without these disease. Multimorbidity was associated with increased
non-participation likelihood. E.g. having 3 or more diseases was associated with 58 % increased non-participation
likelihood (95 % CI: 27–96 %). Higher non-participation was also observed for women with severe multimorbidity
(PR = 1.53, 95 % CI: 1.23–1.90) and mental-physical multimorbidity (PR = 1.54, 95 % CI: 1.36–1.75).
Conclusion: In conclusion, we found a strong association between non-participation in breast cancer screening
for some chronic diseases and for multimorbidity. The highest propensity not to participate was observed for
women with hospital contacts related to the chronic disease in the period closest to the screening date.
Keywords: Chronic disease, Multimorbidity, Breast cancer screening, Mammography screening, Participation,
Non-attendance, Denmark
Background
Breast cancer is the second most common cancer type
worldwide and the most common cancer type among
Danish women [1, 2]. Breast cancer screening can detect
breast cancer at an early stage where the prognosis for
survival is better [3]. Breast cancer screening has there-
fore been introduced as a universal programme in many
western countries. In Denmark, women between 50 and
69 years of age are invited biennially to a mammogram
free of charge [3].
A growing proportion of people are living with chronic
diseases and multimorbidity [4, 5]. Studies have found that
comorbidity increases the mortality risk among breast
cancer patients [6, 7] which in some studies have been
related to the comorbidities rather than to the breast
cancer [6, 8]. Yet, the cancer prognosis depends on the
disease stage at the time of diagnosis [3], and given the in-
creased mortality rate among breast cancer patients with
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chronic diseases, this group may benefit particularly from
early diagnosis.
The association between chronic diseases, multimor-
bidity and non-participation in breast cancer screening
has not been studied sufficiently [9, 10]. Some studies
have investigated diseases individually and their results
are not consistent [9–14]. Five studies found that multi-
morbidity increased non-participation [9, 13, 15–17],
but Heflin et al. [10] found in their study that three or
more conditions increased the propensity to participate.
Although chronic diseases are long-lasting by defin-
ition, patients may experience periods where the disease
is not followed at hospital but rather by primary care,
e.g., during a stable disease period [18]. We hypothesised
that being diagnosed with diseases that involve hospital
contact close to the screening date affects screening
behaviour more than the presence of chronic diseases
without recent hospital contact. To our knowledge, this
issue has not been studied before.
This study has two purposes: first, to analyse whether
being diagnosed with specific chronic diseases or with
multimorbidity is associated with non-participation in
breast cancer screening and, second, to study whether
any such association varies with respect to the time that
has elapsed since the disease required contact to the
hospital sector with the investigated diseases. We
hypothesised that women with chronic diseases and
multimorbidity were more likely not to participation.
Methods
Setting
The setting for the study was the Central Denmark
Region (1.2 million inhabitants, approx. 150,000 women
aged 50–69). Breast cancer screening was introduced as
an organised, universal and free-of-charge programme in
2008–09 in the Central Denmark Region where 78.9 %
of the invited women participated [19].
Study design and population
We conducted an observational, registry-based, histor-
ical cohort study with screening participation as the
outcome and we assessed registrations of chronic dis-
eases up to ten years before the scheduled screening
date. The population comprised women invited to the
first organised breast cancer screening round in the
Central Denmark Region in 2008–09 (N = 149,234)
and we excluded women who were dead or have
moved between the invitations were send out and the
screening date or were outside the caption area (n = 324)
and women with registration of breast cancer in the Danish
Cancer Registry [20] (n = 4,646). In total, 144,264 women
were included; see more information in our previous
publication [19].
Data collection and variables
Information on participation in breast cancer screening
was obtained from a regional administrative database
containing individual information on, e.g., participation
status, the scheduled screening date and the unique cen-
tral registration number (CRN) possessed by all Danes
[21]. The present study is based on data from the preva-
lent screening round in the Central Denmark Region.
Hence, a woman was defined as a participant if she had
participated in the first organised breast cancer screening
round in the Central Denmark Region and as a non-
participant if she had not.
All data described in this section were linked using the
unique CRN number [21].
Data on chronic diseases were drawn from the Danish
National Patient Registry (NPR) [22]. The registry was
founded in 1977 and initially included admission infor-
mation. Since 1995, the registry has expanded to include
information on all outpatient and emergency contacts.
All contacts are registered with a main diagnosis (i.e. ac-
tion diagnosis) based on the International Classification
of Diseases, 10th version (ICD-10) [22]. Data on psychi-
atric diseases were drawn from the Danish Psychiatric
Central Research Register (PCRR). All Danish psychiatric
departments document every contact to the PCRR, and
ICD-10 codes for each hospital admission, outpatient
and emergency contacts were available for the entire
study period [23].
The chronic diseases of interest were selected based
on a recent literature review [24], which recommended
the inclusion of 11 core chronic diseases when assessing
multimorbidity. Based on their recommendations and
another study in the field [25], we included a larger
number of specific chronic diseases and grouped these
diseases into 11 comprehensive chronic disease groups
(CDGs) on which data were drawn from the NPR and
the PCRR. The following CDGs were included: diabetes,
hypertension, cancer, chronic obstructive pulmonary dis-
ease (COPD), cardiovascular diseases, chronic arthritis,
chronic kidney disease, chronic liver disease, chronic
neurological disorders, chronic bowel disease and chronic
mental illness (Additional file 1).
Multimorbidity was operationalised as follows: “Multi-
morbidity” covers the co-occurrence of two or more
chronic diseases from two or more of the CDGs. “Severe
multimorbidity” designates the co-occurrence of three or
more chronic diseases from three or more of the CDGs.
“Physical multimorbidity” describes the co-occurrence of
two or more physical CDGs, but without the mental
CDG. “Physical-mental multimorbidity” signifies the co-
occurrence of at least one physical CDG and the mental
CDG. Thus, a woman could be categorised as having more
than one type of multimorbidity; e.g. severe multimorbidity
and physical multimorbidity. Finally, we measured “disease
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counts” within the categories: 0, 1, 2, ≥3 CDGs, with the
latter category being combined due to few occurrences.
Study participants were categorised with one of the
diseases mentioned above if they had an emergency con-
tact, an outpatient contact or an admission with one of
the selected diseases to any Danish hospital during the
10 years period before screening. We intended to study
if an association varied with time as we hypothesised
that the likelihood of non-participation would be stron-
ger for women with a chronic disease requiring hospital
attention in the period leading up to screening com-
pared to women with chronic diseases that did not re-
quire hospital attention in the period leading up to
screening. Because of this, data on the 10-year follow-up
were stratified into two time periods which were not
mutually exclusive: (1) any hospital contact with the in-
cluded chronic diseases ≤2 years (i.e. 0–730 days) before
the screening date; and (2) hospital contacts with the in-
cluded chronic diseases >2–10 years (i.e. 731–3652 days)
before the screening date. Thus, a woman could be cate-
gorised in both groups if she was registered in the NPR
or PCRR with a given disease in both time periods.
E.g.55 % of all women was registered with rheumatoid
arthritis in both time periods (data not shown).
We obtained individual data on the population’s socio-
economic position (SEP) registered the year of the
scheduled screening date from Statistics Denmark [26]
and included: ethnicity categorised as 1) Danish and de-
scendants of immigrants and 2) immigrants. Marital
status was categorised as married/cohabitating and sin-
gle. Education was classified according to the UNESCO
classification [27] as low (≤10 years), middle (11–15
years) and higher (>15 years). Finally, age on the date of
the scheduled screening was included as a continuous
variable in the multivariate analyses.
Finally, almost all Danish citizens (98 %) are listed with
a specific general practitioner (GP) or general practice
[28], and data on GP attachment were obtained from the
Danish National Health Service Registry which was used
to do cluster adjustments by GP affiliation.
Statistical analysis
All analyses were performed using Stata 13.1. Prevalence
ratios (PRs) with 95 % confidence intervals (95 % CI)
were estimated using generalised linear models (GLM)
[29, 30]. PRs were chosen over the odds ratio, as it has
been found to overestimate associations when the out-
come is frequent [30].
Unadjusted analyses were conducted for each of the
CDGs. We compared women having each specific CDG
with women without the CDG in question. In model 1,
we adjusted for SEP (ethnicity, marital status, education
and age). In model 2, we adjusted for the variables in
model 1 (SEP) and for the coexistence of the other
included diseases. We also hypothesised that an associ-
ation between one given disease and non-participation
in one time period could be confounded by having
chronic diseases in the other time period. Therefore, we
also adjusted model 2 for being registered in the NPR or
PCRR in the other time period.
Unadjusted analyses were also conducted for the mul-
timorbidity variables. Model 1 adjusted for SEP (ethni-
city, marital status, education and age). Model 2
adjusted for the variables in model 1 (SEP) and for being
registered in the NPR or PCRR with multimorbidity in
the other time period. E.g. when studying severe multi-
morbidity >2–10 years before the scheduled screening
date, we adjusted for SEP and for having severe multi-
morbidity in the period ≤2 years before the scheduled
screening date.
We assessed the association between the latest hospital
contact with either of the included diseases and non-
participation with a cubic spline model, using the
method proposed by Orsini and Greenland and knots
were set at 5, 27.5, 50, 72.5 and 95 percentiles [31, 32].
All analyses were assessed with robust variance esti-
mates to adjust for clustering of patients in general prac-
tices. This was done as practice clustering might be
related to the propensity to be diagnosed with a
chronic disease and also to participate in breast can-
cer screening [33].
Ethical approvals
No ethical approval was required according to Danish
legislation and the National Committee on Health
Research Ethics in the Central Denmark Region as the
study was based on registry and survey data (j. no. 181/
2011). Approval for data on screening behaviour was
granted from the Central Denmark Regions legal depart-
ment (j. no.: 1-16-02-109-09) and permission for the na-
tional registry data was granted from by the Danish Data
Protection Agency (j. no.: 2009-41-3471).
Results
Study population social-characteristics
A higher non-participation proportion was found
among women in the oldest age group, single women,
women with non-Danish origin and with low educa-
tion (Table 1).
CDGs and non-participation in breast cancer screening
In total, 20.3 % of women without a chronic disease did
not participate in the first screening round whereas
28.6 % women with minimum one of the chronic dis-
eases did not participate (Table 1). For most of the
CDGs, women who had a chronic condition were more
inclined to abstain from participation than women who
had no chronic diseases except for hypertension and
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chronic arthritis. The participation proportion was
higher for women with chronic bowel disease than for
women without chronic bowel disease (Table 2).
In model 2, having cancer, mental illness, COPD, chronic
neurological disorder and chronic kidney disease signifi-
cantly increased the likelihood of non-participation in both
time periods, whereas having bowel disease increased the
likelihood of participation (PRmodel2 = 0.75, 95 % CI: 0.65–
0.88) (Table 3). Diabetes was insignificantly related to
screening ≤2 years before the screening date; but if the lat-
est hospital contact was between >2–10 years before the
screening date, women with diabetes were significantly less
likely to participate. For women with chronic liver disease
and cardiovascular disease, non-participation became insig-
nificant in model 2. Hypertension and chronic arthritis
were significantly associated with higher participation if
the last hospital contact was >2–10 years before the
screening date, but not if it was ≤2 years before screening
(Table 3).
Multimorbidity and non-participation in breast cancer
screening
Overall, non-participation was more common among
women with multimorbidity and a higher disease count
(Table 4). In the regression analyses, the disease-count
variable showed an increased non-participation likelihood
with each additional disease compared with no disease
(e.g. 3 diseases: PRmodel 2 = 1.58, 95 % CI: 1.27–1.96)
(Table 5). Women with any of the multimorbidity aspects
were significantly more likely not to participate than were
women without multimorbidity. This applied in both time
periods, but the estimates were highest for hospital con-
tact ≤2 years before the screening date. In general, the as-
sociations between the different types of multimorbidity
and non-participation were largely similar. However, hav-
ing severe multimorbidity (≥3 diseases) was associated
with a somewhat higher non-participation propensity
(PRmodel2 = 1.53, 95 % CI: 1.23–1.90) than having multi-
morbidity (≥2 diseases) (PRmodel2 = 1.38, 95 % CI: 1.29–
1.49). Non-participation likelihood was also somewhat
higher for women with physical-mental multimorbidity
than women with physical multimorbidity (PRmodel2 =
1.54, 95 % CI: 1.36–1.75 and PRmodel2 = 1.37, 95 % CI:
1.26–1.49, respectively) (Table 5).
The association between the latest hospital contacts
with any of the included diseases indicated a non-
linear association. Non-participation was highest when
the latest hospital occurred in the year leading up to
screening and the PR of non-participation did not dif-
fer markedly if the latest hospital contact occurred 6
or more years before screening (data not shown).
Discussion
This large population-based cohort study revealed that
women with cancer, mental illness, COPD, neurological
disorders or kidney disease had an increased likelihood
of non-participation in breast cancer screening. The like-
lihood of non-participation increased with the number
of co-existing diseases and was particularly high for
women with severe multimorbidity and mental-physical
multimorbidity. The associations were in general stron-
gest when the women had hospital based contacts with
the disease in the period ≤2 years before screening com-
pared to when the contacts had occurred > 2 to 10 years
before screening. Sub-analysis indicated that the likeli-
hood of non-participation was affected the most if the
latest hospital contact occurred up to one year before
screening.
Strengths and limitations
Data on screening participation were obtained from an
administrative registry with no missing information and
no reliance on self-reported data. The cohort comprised
a well-defined population, i.e. the prevalent screening
round in the Central Denmark Region; and using the
CRN, we were able to identify and follow the entire
population and can therefore exclude selection bias.
Table 1 Socio-economic position of the study population
divided according to participation in the screening programme
(n = 144,264, numbers vary due to missing observations)
All women
Participants Non-participants P-value
(chi2)N (% column) N (% column)
113,811 (79.1) 30,453 (21.1)
Chronic disease (no missings)a <0.001
No 104,012 (79.7) 26,533 (20.3)
Yes 9,799 (71.4) 3,920 (28.6)
Age on the screening date (no missings) <0.001
50–54 years 30,965 (80.4) 7,536 (19.6)
55–59 years 30,722 (80.2) 7,580 (19.8)
60–64 years 30,532 (79.2) 7,998 (20.8)
65–69 years 21,592 (74.6) 7,339 (25.4)
Marital status (missing N = 83 (0.06 %)) <0.001
Married/cohabiting 88,590 (82.7) 18,484 (17.3)
Single 25,183 (67.9) 11,924 (32.1)
Ethnicity (missing N = 48 (0.03 %)) <0.001
Danish/descendant 110,018 (79.6) 28,201 (18.3)
Immigrants 3,773 (62.9) 2,224 (37.1)
Education (missing N = 2,279 (1.6 %)) <0.001
≤ 10 years 39,214 (75.6) 12,651 (24.4)
11–15 years 47,661 (81.8) 10,624 (18.2)
> 15 years 25,549 (80.2) 6,286 (19.7)
(n = 144,264, numbers vary due to missing observations)
aPresence of chronic diseases ≤2 years before the scheduled screening date
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We included chronic diseases as registered in nationwide
registries containing information on all hospital-related
contacts in Denmark [22, 23]. The validity of the registries
has been established for several of the included diseases
[34–36]. However, these registers do not contain informa-
tion on treatment in general practice; thus the results of
this study apply only to patients with hospital-requiring
treatment. Patients who are treated only in general practice
will in our analysis appear in the reference group but be-
cause our reference group is very large this proportion will
presumably be small and will probably not affect the results
markedly. As no Danish registers contains data on routine
treatment from general practice, it was not possible to
study or adjust for this in the present study.
Table 2 Distribution of women with the selected CDGs ≤2 years and >2–10 years before screening and screening participation
(n = 144,264)
Contacts to hospital with the CDGs ≤2 years
before the screening date
Contacts to hospital with the CDGs >2–10 years
before the screening date
Chronic diseases Participants Non-participants Participants Non-participants
N (% row) N (% row) P-value (chi2) N (% row) N (% row) P-value (chi2)
Cardiovascular diseases <0.001 <0.001
No 111,578 (79.0) 29,670 (21.0) 108,916 (79.0) 28,885 (21.0)
Yes 2,233 (74.0) 783 (26.0) 4,895 (75.7) 1,568 (24.3)
Cancer <0.001 <0.001
No 112,517 (79.1) 29,780 (20.9) 111,848 (79.0) 29,798 (21.0)
Yes 1,294 (65.8) 673 (34.2) 1,963 (75.0) 655 (25.0)
Hypertension 0.944 0.844
No 112,475 (78.9) 30,097 (21.1) 110,753 (78.9) 29,641 (21.1)
Yes 1,336 (78.9) 356 (21,0) 3,058 (79.0) 812 (21.0)
Chronic mental illness <0.001 <0.001
No 112,683 (79.1) 29,696 (20.9) 111,261 (79.3) 28,970 (20.7)
Yes 1,128 (59.8) 757 (40.2) 2,550 (63.2) 1,483 (36.8)
Diabetes <0.001 <0.001
No 112,116 (79.0) 29,836 (21.0) 111,801 (79.1) 29,609 (20.9)
Yes 1,695 (73.3) 617 (36.7) 2,010 (70.4) 844 (29.6)
Chronic obstructive pulmonary disease <0.001 <0.001
No 112,975 (79.1) 29,917 (20.9) 112,439 (79.1) 29,709 (20.9)
Yes 836 (60.9) 536 (39.1) 1,372 (64.8) 744 (35.2)
Chronic neurological disorders <0.001 <0.001
No 113,234 (78.9) 30,188 (21.1) 113,049 (79.0) 30,078 (21.0)
Yes 577 (68.5) 265 (31.5) 762 (67.0) 375 (33.0)
Chronic arthritis 0.079 0.439
No 113,083 (78.9) 30,254 (21.1) 112,865 (78.9) 30,186 (21.1)
Yes 728 (78.5) 199 (21.5) 946 (78.0) 267 (22.0)
Chronic bowel disease 0.004 <0.001
No 113,185 (78.9) 30,326 (21.1) 112,905 (78.9) 30,272 (21.1)
Yes 626 (83.1) 127 (16.9) 906 (83.3) 181 (16.7)
Chronic liver disease <0.001 <0.001
No 113,606 (78.9) 30,367 (21.1) 113,567 (78.9) 30,343 (21.1)
Yes 205 (70.4) 86 (29.6) 244 (68.9) 110 (31.1)
Chronic kidney disease <0.001 <0.001
No 113,684 (78.9) 30,341 (21.1) 113,655 (78.9) 30,355 (21.1)
Yes 127 (53.1) 112 (46.9) 156 (61.4) 98 (38.6)
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In this study, chronic diseases and multimorbidity
were specified based on leading studies in the field
[24, 25]. However, generalisations cannot be made
about chronic diseases in general as the study included
only some and not all existing chronic diseases. The
chronic diseases that were selected were categorised into
groups of chronic diseases (see Additional file 1) since we
believe that the practical implications of the results would
be relevant to more people. Moreover, combining, e.g.,
several mental diseases with a varying degree of severity
and chronicity might lead to less nuanced findings for this
group of patients.
Table 3 PR of screening non-participation by the selected CDGs ≤2 years and >2–10 years before screening (n = 144,264)
Unadjusted Model 1a Model 2b
≤2 years >2–10 years ≤2 years >2–10 years ≤2 years >2–10 years
PR (95 % CI) PR (95 % CI) PR (95 % CI) PR (95 % CI) PR (95 % CI) PR (95 % CI)
Cardiovascular diseases
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1.24 (1.16–1.31) 1.16 (1.11–1.21) 1.13 (1.06–1.21) 1.04 (0.99–1.09) 1.05 (0.99–1.13) 0.98 (0.93–1.02)
Cancer
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1.63 (1.54–1.74) 1.19 (1.11–1.27) 1.56 (1.46–1.66) 1.16 (1.08–1.24) 1.50 (1.40–1.60) 1.10 (1.03–1.17)
Hypertension
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1.00 (0.91–1.09) 0.99 (0.93–1.06) 0.97 (0.87–1.07) 0.97 (0.91–1.04) 0.92 (0.83–1.02) 0.93 (0.87–0.99)
Chronic mental illness
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1.93 (1.82–2.04) 1.78 (1.71–1.86) 1.62 (1.53–1.71) 1.51 (1.44–1.57) 1.51 (1.42–1.60) 1.40 (1.35–1.46)
Diabetes
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1.27 (1.19–1.36) 1.41 (1.33–1.50) 1.14 (1.06–1.22) 1.23 (1.17–1.31) 1.05 (0.97–1.13) 1.10 (1.04–1.17)
Chronic obstructive pulmonary disease
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1.87 (1.75–1.99) 1.68 (1.59–1.78) 1.62 (1.52–1.73) 1.43 (1.35–1.52) 1.51 (1.42–1.62) 1.32 (1.24–1.40)
Chronic neurological disorders
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1.50 (1.35–1.65) 1.57 (1.44–1.71) 1.36 (1.23–1.50) 1.40 (1.29–1.52) 1.24 (1.12–1.37) 1.23 (1.13–1.34)
Chronic arthritis
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1.02 (0.90–1.15) 1.04 (0.94–1.16) 0.97 (0.86–1.10) 0.99 (0.89–1.11) 0.90 (0.80–1.02) 0.89 (0.80–1.00)
Chronic bowel disease
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 0.80 (0.68–0.94) 0.79 (0.69–0.90) 0.81 (0.69–0.94) 0.78 (0.68–0.89) 0.75 (0.65–0.88) 0.71 (0.61–0.81)
Chronic liver disease
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1.40 (1.17–1.67) 1.47 (1.26–1.72) 1.20 (1.00–1.43) 1.24 (1.06–1.43) 1.12 (0.93–1.34) 1.08 (0.92–1.26)
Chronic kidney disease
No 1 (ref) (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 2.22 (1.94–2.55) 1.83 (1.57–2.14) 1.93 (1.69–2.20) 1.61 (1.36–1.90) 1.70 (1.49–1.94) 1.40 (1.19–1.65)
aAdjusted for age, ethnicity, marital status and education
bAdjusted for age, ethnicity, marital status, education, for being registered in the NPR or PCRR with the other studied chronic diseases, and for being registered in
the NPR or PCRR with one of the CDGs in the other time period (yes/no). E.g. cancer 0–2 year before screening is adjusted for SEP, for the remaining 10 studied
diseases and for being in hospital contact with one of the 11 included chronic disease groups >2–10 years before screening
Statistically significant results in bold
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Chronic diseases, multimorbidity and screening behaviour
A previous cancer diagnosis (other than breast cancer)
was related to non-participation in both time periods.
Several explanations for this finding can be suggested.
First of all, some women may have attended a post-
cancer follow-up programme and therefore did not find
it relevant to participate in screening. Others may have
been too ill to participate, or they may have been in a
palliative phase. Some may have been unrealistically op-
timistic [37] and may not have perceived themselves as
being at risk of being diagnosed with yet another type of
cancer. Conversely, others may have avoided anything
relating to cancer because of the trauma experienced by
having the first cancer diagnosis. Notwithstanding, it has
been shown that some previous cancer types increases
the risk of developing later breast cancer [38–40], which
makes these results important as this group may benefit
particularly from early detection of cancer.
Having chronic bowel disease was the only CDG that
significantly increased the propensity to participate in
breast cancer screening in both time periods. Chronic
bowel disease often has an early onset in life compared
with the other included diseases and being diagnosed
with this disease often involves continuous health-care
follow-up. These women may therefore have been
‘schooled’ from early on in life to engage in healthy life-
styles and may be used to having various contacts with
the healthcare system and undergoing tests [41, 42]. A
study from 2014 also found higher likelihood of having
followed a recommended breast cancer screening
programme among women with digestive disease com-
pared to women without any digestive disease [13].
Taken together, this seems to indicate that having a
bowel/digestive-related disease has a positive impact on
screening behaviour. Having cardiovascular diseases was
not associated with non-participation after adjustments,
a finding which is supported by other studies [11, 43]
but not all [13]. Having hypertension, chronic arthritis
and diabetes up to 2 years before screening were not as-
sociated with screening participation. However, if the lat-
est contact was >2–10 years before screening, having
hypertension and arthritis increased participation signifi-
cantly, and having diabetes increased non-participation.
The underlying mechanisms here are unclear, but they
could, e.g., be related to these women’s lifestyles, an
issue which should be studied further.
This study shows that having multimorbidity increases
non-participation. This is supported by five other studies
[9, 13, 15–17], even if one of these studies found an as-
sociation for women ≥75 years only [17]. Another study,
conducted in the USA and based on self-reported data,
found the opposite; namely that multimorbidity increased
participation [10]. The authors argue that women with
multimorbidity have more frequent contact with the GP
Table 4 Distribution of women with multimorbidity ≤2 years and >2–10 years before screening and their participation status
(n = 144,264)
Contacts to hospital with the CDGs ≤2 years
before the screening date
Contacts to hospital with the CDGs >2–10 years
before the screening date
Participants Non-participants Participants Non-participants
N (% row) N (% row) P-value (chi2) N (% row) N (% row) P-value (chi2)
Disease count <0.001 <0.001
0 104,012 (79.7) 26,533 (20.3) 97,440 (79.8) 24,598 (20.2)
1 8,887 (72.4) 3,383 (27.6) 14,153 (74.8) 4,763 (25.2)
2 845 (63.4) 488 (36.6) 1,966 (67.7) 939 (32.3)
≥ 3 67 (57.8) 49 (42.2) 252 (62.2) 153 (37.8)
Multimorbidity (≥2 diseases) <0.001 <0.001
No 112,899 (79.0) 29,916 (21.0) 111,593 (79.2) 29,361 (20.8)
Yes 912 (62.9) 537 (37.1) 2,218 (67.0) 1,092 (33.0)
Severe multimorbidity (≥3 diseases) <0.001 <0.001
No 113,744 (78.9) 30,404 (21.1) 113,559 (78.9) 30,300 (21.1)
Yes 67 (57.8) 49 (42.2) 252 (62.2) 153 (37.8)
Physical multimorbidity <0.001 <0.001
No 113,043 (79.0) 30,032 (21.0) 112,045 (79.0) 29,654 (20.9)
Yes 768 (64.6) 421 (35.4) 1,766 (68.8) 799 (31.2)
Physical-mental multimorbidity <0.001 <0.001
No 113,657 (78.9) 30,320 (21.1) 113,269 (79.0) 30,099 (21.0)
Yes 154 (53.7) 133 (46.3) 542 (60.5) 354 (39.5)
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who plays a direct role in advising women to participate in
screening in the USA [10]. However, the other studies
which found the opposite were also conducted in the USA.
The association between chronic diseases, multimorbidity
and non-participation may be explained by several factors.
Women with one or more chronic diseases may not feel
well enough to participate, and the competing demands in
relation to managing their chronic disease(s) may take up
all their energy [9, 18]. It has also been raised as a possible
explanation that non-participation among diseased women
is based on deliberate decisions from the patient (or their
GP) based on an evaluation of costs and benefits, taking
into account the severity of the disease, reduced quality of
life and shortened life expectancy [9, 15].
This study is the first to include different time periods
for hospital contacts. For most diseases and all aspects
of multimorbidity, the estimates were strongest for
the ≤ 2 year period before the screening date. Some studies
have adjusted for e.g. “number of years with illness/in con-
tact with clinic” or “number of contacts” [9, 13, 15, 16],
but no study has evaluated whether the associations de-
pend on elapsing time since last hospital contact. Thus,
these results add to the current literature as it highlights
that non-participation is especially challenged when the
woman is affected by the disease in the period leading up
to the screening appointment.
This study clearly indicates that women with some of
the studied chronic diseases and women with multimor-
bidity are not engaging in screening to the same extent
as their female counterparts who do not have the se-
lected CDGs and multimorbidity. As these women are
more frequently in contact with the health care system,
this may make it easier to inform them about the advan-
tages of screening for early diagnosis. This group of
women may also derive particular benefits from their
general practitioner playing a more active role discussing
with them the pros and cons of breast cancer screening.
Conclusion
In conclusion, this study indicates increased non-
participation in breast cancer screening for women
who previously have been in contact with the second-
ary healthcare system for some of the selected CDGs.
Non-participation was strongly associated with having
multimorbidity. Strongest associations were found
when the hospital contacts for the diseases had oc-
curred in the recent period before screening. Women
suffering from chronic diseases or multimorbidity may
achieve health gains from early detection of cancer
owing to their participation in screening; and their
participation could with possible benefit be encouraged
by healthcare professionals.
Table 5 PR of screening non-participation by multimorbidity ≤2 years and >2–10 years before screening (n = 144,264)
Unadjusted Model 1a Model 2b
≤2 years >2–10 years ≤2 years >2–10 years ≤2 years >2–10 years
PR (95 % CI) PR (95 % CI) PR (95 % CI) PR (95 % CI) PR (95 % CI) PR (95 % CI)
Disease count
0 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
1 1.36 (1.32–1.40) 1.25 (1.22–1.28) 1.25 (1.21–1.29) 1.14 (1.11–1.18) 1.20 (1.16–1.24) 1.08 (1.04–1.11)
2 1.80 (1.68–1.39) 1.60 (1.52–1.69) 1.55 (1.45–1.67) 1.38 (1.31–1.45) 1.47 (1.36–1.58) 1.25 (1.18–1.32)
≥ 3 2.08 (1.68–2.57) 1.87 (1.65–2.12) 1.69 (1.36–2.09) 1.52 (1.33–1.73) 1.58 (1.27–1.96) 1.33 (1.17–1.52)
Multimorbidity (≥2 diseases)
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1.77 (1.65–1.89) 1.58 (1.51–1.66) 1.52 (1.42–1.63) 1.36 (1.30–1.43) 1.38 (1.29–1.49) 1.28 (1.22–1.35)
Severe multimorbidity (≥3 diseases)
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 2.00 (1.62–2.48) 1.79 (1.58–2.03) 1.63 (1.31–2.02) 1.47 (1.29–1.67) 1.53 (1.23–1.90) 1.44 (1.26–1.64)
Physical multimorbidity
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 1.69 (1.56–1.82) 1.49 (1.40–1.58) 1.47 (1.36–1.59) 1.30 (1.23–1.38) 1.37 (1.26–1.49) 1.23 (1.16–1.31)
Physical-mental multimorbidity
No 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Yes 2.20 (1.94–2.49) 1.88 (1.73–2.04) 1.80 (1.60–2.02) 1.52 (1.40–1.66) 1.54 (1.36–1.75) 1.42 (1.30–1.56)
aAdjusted for age, ethnicity, marital status and education
bAdjusted for age, ethnicity, marital status, education, and for being registered in the NPR or PCRR with the studied multimorbidity in the other time period (yes/
no). E.g. severe multimorbidity 0–2 year is adjusted for SEP, and for being in hospital contact with 3 or more chronic disease groups >2-10 years before screening
Statistically significant results in bold
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